CHI3L1 and breast cancer: Interestingly, Roslind et al. claimed that serum concentrations of YKL-40 may provide a more consistent biomarker of a specific patient’s disease progression as intratumoral YKL-40 expression can vary across a single breast cancer nodule [16].